Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2023-06-19 Regulatory Filings
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Grant Success for Glioblastoma studies
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 0732D' and contains standard regulatory announcement formatting, including contact details for a Nominated Advisor (FinnCap) and a PR firm (Instinctif Partners). The content announces a specific corporate event: receiving notification of a grant success for pre-clinical and clinical studies. This type of announcement, which is a formal update to the market regarding a specific, non-financial event (like a grant award or partnership update), is typically disseminated via the Regulatory News Service (RNS). Since it is a specific corporate announcement that doesn't fit the definitions for ER, IR, 10-K, or CAP, the most appropriate classification is the general regulatory announcement category, RNS.
2023-06-19 English
Final Results
Annual Report Classification · 95% confidence The document is an official announcement from Evgen Pharma PLC regarding its 'Full year Results' for the year ended 31 March 2023. It contains a comprehensive summary of operational highlights, financial highlights (including post-tax loss and cash position), a Chairman's statement, and a Chief Executive's review. While it is titled 'Full year Results', it functions as the primary annual financial disclosure for the company, which aligns with the definition of an Annual Report (10-K equivalent for UK-listed companies). FY 2023
2023-06-07 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is titled "Notice of Full Year Results" and explicitly states that the company "will report its full year results for the financial year ended 31 March 2023 on Wednesday, 7 June 2023." This is a short announcement informing the market about the future release date of a major report (Full Year Results, typically a 10-K or equivalent). According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report falls under Report Publication Announcement (RPA). It is not the full report itself, nor is it a general regulatory filing (RNS) since a more specific category exists for announcing report publication dates.
2023-05-26 English
Preliminary results from Phase 1b study
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 7820T' and is dated March 22, 2023. It announces preliminary pharmacokinetic results from a Phase 1b study for a drug candidate (SFX-01). This is a typical announcement of clinical trial data updates, which is a form of corporate news release. Since it is not a full Annual Report (10-K), a specific financial release (ER), or a formal presentation (IP), and it is clearly a regulatory news service announcement (RNS), the most appropriate general category is Regulatory Filings (RNS), as it is a miscellaneous regulatory announcement not covered by more specific codes like DIV, CAP, or ER. The document is short enough (7529 chars) that it is an announcement, not the full detailed report itself, but RNS is the best fit for this type of market-sensitive, non-standard filing.
2023-03-22 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated March 16, 2023. The content discusses a 'Price Monitoring Extension' for a security on the London Stock Exchange, which is a specific operational announcement related to trading mechanisms. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a general regulatory announcement disseminated via the RNS system that does not fit into the more specific categories like ER, 10-K, or DIV. Therefore, the most appropriate classification is the general Regulatory Filings category.
2023-03-16 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1931 characters) and contains the header 'RNS Number : 2314T'. It discusses a 'Second Price Monitoring Extension' related to trading activity, which is a specific operational announcement on the stock exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates it is a general regulatory announcement that does not fit into the specific categories like ER, 10-K, or DIV. Therefore, the most appropriate classification is the general regulatory filing fallback category.
2023-03-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.